OvaScience Inc (NASDAQ:OVAS) has received a consensus recommendation of “Hold” from the six ratings firms that are currently covering the firm. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $8.00.

Several equities research analysts have weighed in on OVAS shares. Zacks Investment Research upgraded OvaScience from a “hold” rating to a “buy” rating and set a $1.75 price target on the stock in a report on Wednesday, February 8th. Oppenheimer Holdings Inc. restated a “hold” rating on shares of OvaScience in a report on Saturday, March 4th. Credit Suisse Group AG restated an “underperform” rating and set a $1.00 price target on shares of OvaScience in a report on Tuesday, April 18th. Finally, HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of OvaScience in a report on Friday, May 12th.

COPYRIGHT VIOLATION WARNING: This news story was first posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/05/19/ovascience-inc-ovas-receives-average-rating-of-hold-from-analysts-2.html.

Several hedge funds have recently made changes to their positions in OVAS. Teachers Advisors LLC boosted its stake in shares of OvaScience by 53.0% in the fourth quarter. Teachers Advisors LLC now owns 68,249 shares of the biotechnology company’s stock worth $104,000 after buying an additional 23,643 shares during the period. UBS Asset Management Americas Inc. purchased a new stake in shares of OvaScience during the first quarter worth about $107,000. Northern Capital Management LLC boosted its stake in shares of OvaScience by 92.6% in the first quarter. Northern Capital Management LLC now owns 91,865 shares of the biotechnology company’s stock worth $172,000 after buying an additional 44,175 shares during the period. Morgan Stanley boosted its stake in shares of OvaScience by 2.8% in the first quarter. Morgan Stanley now owns 160,363 shares of the biotechnology company’s stock worth $300,000 after buying an additional 4,394 shares during the period. Finally, KCG Holdings Inc. purchased a new stake in shares of OvaScience during the first quarter worth about $375,000. 79.61% of the stock is owned by hedge funds and other institutional investors.

Shares of OvaScience (NASDAQ:OVAS) traded down 0.75% during midday trading on Friday, reaching $1.32. The company had a trading volume of 100,045 shares. OvaScience has a 52 week low of $1.30 and a 52 week high of $10.09. The company’s 50 day moving average price is $1.50 and its 200-day moving average price is $2.08. The company’s market capitalization is $47.07 million.

OvaScience (NASDAQ:OVAS) last issued its quarterly earnings results on Tuesday, May 9th. The biotechnology company reported ($0.38) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.46) by $0.08. OvaScience had a negative return on equity of 62.66% and a negative net margin of 11,642.67%. The company had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.12 million. During the same quarter in the prior year, the business earned ($0.80) EPS. OvaScience’s revenue was down 56.8% on a year-over-year basis. On average, equities research analysts predict that OvaScience will post ($1.58) earnings per share for the current fiscal year.

OvaScience Company Profile

OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.

5 Day Chart for NASDAQ:OVAS

Receive News & Ratings for OvaScience Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience Inc and related companies with MarketBeat.com's FREE daily email newsletter.